Raydiant Oximetry is a Rosenman Innovator.


Read the full story at the Fogarty Institute website.

When Neil Ray, MD, founder and CEO of Fogarty Institute graduate Raydiant Oximetry and  a board-certified anesthesiologist, learned about the global shortage  of ventilators early in the COVID-19 crisis, he immediately considered  ways that he, his colleagues and others in the Silicon Valley medtech  ecosystem could help.

He first reached out to Russ DeLonzor,  Raydiant Oximetry’s COO, who had previous experience working with  ventilators as vice president of R&D at Nellcor Puritan-Bennett,  which is now part of Medtronic’s portfolio, one of the largest medical  device manufacturers of ventilators.

“Given my extensive  experience using ventilators as an anesthesiologist, our experience in  the industry and our network here in Silicon Valley, we were intrigued  and encouraged by the idea of developing a safe, effective,  low-maintenance and inexpensive ventilator that could save the lives of  COVID patients with acute respiratory distress syndrome (ARDS),” said  Neil.

“We were reading headlines regarding physicians in Italy  having to make decisions on who would get a ventilator and who would  potentially be left to die, and articles on U.S. states facing critical  shortages of life-saving equipment. We knew there had to be a better way and had to do something to address this immense need,” added Russ.